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Abstract
Allergen immunotherapy (AIT) is the only currently available immune-modifying and aetiological treatment for
patients suffering from IgE-mediated diseases. In childhood, it represents a suitable therapeutic option to intervene
during the early phases of respiratory allergic diseases such as rhino-conjunctivitis and asthma, which is when their
progression may be more easily influenced. A growing body of evidence shows that oral immunotherapy represents
a promising treatment option in children with persistent IgE- mediated food allergy. The efficacy of AIT is under
investigation also in patients with extrinsic atopic dermatitis, currently with controversial results. Furthermore, AIT might
be a strategy to prevent the development of a new sensitization or of a (new) allergic disease. However, there are still
some methodological criticisms, such as: a) the regimen of administration and the amount of the maintenance dose
are both largely variable; b) the protocols of administration are not standardized; c) the description and classification of
side effects is variable among studies and needs to be standardized; d) quality of life and evaluation of health
economics are overall missing. All these aspects make difficult to compare each study with another. In addition, the
content of major allergen(s) remains largely variable among manufacturers and the availability of AIT products
differences among countries. The interest and the attention to AIT treatment are currently fervent and increasing.
Well-designed studies are awaited in the near future in order to overcome the current gaps in the evidence and
furtherly promote implementation strategies.
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Background
It is estimated that more than one third of population all
over the world is currently suffering from at least one al-
lergic disease [1]. In particular, allergic rhinitis, asthma,
and food allergy represent major disorders. Their inci-
dence is increasing especially in children and young
adults, who are bearing the greatest burden of these
trends together with their families and health services
[1]. Nowadays, most patients have good disease control
and acceptable quality of life through avoidance strategies
and symptomatic drug therapy. However, a minority
still have persistent symptoms or remain at risk of
life-threatening allergic reactions. Allergen-specific im-
munotherapy (AIT) is currently recognized as the only
clinically effective treatment capable of a disease-modifying
effect for IgE-mediated allergic diseases [1–8]. AIT may
not only desensitize a patient -including who is not respon-
sive to avoidance strategies or pharmacotherapy- thereby
ameliorating symptoms while on treatment, but also de-
liver long-term clinical benefits that may persist for years
post-AIT discontinuation. Since the first description of the
clinical efficacy of subcutaneous injections of a pollen ex-
tract in hay-fever, reported by Leonard Noon in 1911 [9],
AIT has been performed (Fig. 1). Typically the subcutane-
ous, sublingual or oral routes are used. Others, such as the
epicutaneous and the intra-lymphatic ones are under in-
vestigation. In the early years, allergenic extracts of poor
quality and definition were used. Substantial progress in
understanding the patho-mechanisms of allergic reactions
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has led to improve both safety and efficacy profile of AIT
in clinical practice. Currently, AIT is accepted and rou-
tinely prescribed worldwide in the pediatric population for
respiratory allergies and more and more in food allergies.
However, there are still several gaps to be filled, particularly
around AIT long-term benefit and its use in children. The
efficacy of AIT is under investigation also in patients with
extrinsic atopic dermatitis, currently with controversial
results [10, 11]. A better understanding in mechanisms of
action of AIT might improve both the clinical efficacy of
the treatment – while permitting shorter, safer and more
convenient strategies for the patient- and the early or even
preliminary recognition of AIT-responders. Well-designed
large scale studies are still needed in order to make AIT a
precision medicine, targeted to the patient.
In the text below, we preliminary synthesize the
current knowledge of the mechanisms of action of AIT.
Afterwards, we describe the current evidence on AIT in
terms of prevention, allergic rhinitis and food allergy.
Finally, the current gaps and plans to address them will
be discussed.
Mechanisms of action of AIT and predictive
biomarkers
AIT works through several immunological pathways
[12, 13]. The mechanisms of action include the induction
of very early desensitization of mast cells and basophils
[14, 15]; generation of specific regulatory T and regulatory
B cell responses [16, 17]; regulation of allergen specific
IgE, IgG4 and IgA [18–21]; decreases in numbers and ac-
tivity of effector cells in mucosal of target organs, includ-
ing mast cells [22], basophils [23], eosinophils [24], and
type 2 innate lymphoid cells [25]; and decreases in the
activity of basophils in circulation [9] (Fig. 2). However, a
detailed knowledge of the mechanism involved in effective
AIT is still missing. Furthermore, it is not clear whether
the altered long-term memory resides within the T-cell or
the B-cell compartment. Understanding mechanisms
underlying induction and persistence of tolerance is a key
point in order both to identify novel and more effective
strategies tailored on the individual pattern and to
establish predictive biomarkers of clinical response. So far,
several biomarkers candidates have been investigated: IgE
[total IgE, specific IgE (sIgE) and sIgE/Total IgE ratio);
IgG-subclasses (sIgG1, sIgG4 including sIgE/IgG4 ratio);
serum inhibitory activity for IgE (IgE-FAB and IgE-BF);
basophil activation; cytokines and chemokines; cellular
markers (T regulatory cells, B regulatory cells and den-
dritic cells) and in vivo biomarkers (e.g. provocation tests)
[26]. In particolar, IgE specific activity (ratio specific IgE/
total IgE) and serum IgE-FAB are currently considered as
potential surrogate candidate biomarkers; however data
are discordant [26]. To explore the use of allergen-specific
IgG4 is recommended as a biomarker for compliance.
More studies for confirmation and interpretation of the
possible association with the clinical response to AIT are
still needed.
Status of the art, unmet needs and future
perspectives
General considerations
Several studies have investigated the efficacy and safety
of AIT [5–7]. However, to interprete the current evi-
dence remains challenging for the deep heterogeneity
among studies. For instance, they are evaluating different
populations. It is known that atopic heredity play a role
in the risk of developping allergic disease(s). Further-
more, children with atopic sensitization and/or early
manifestations of atopic diseases (such as atopic derma-
titis and food allergy) have a higher risk for development
of other allergic manifestations (e.g. asthma) [27–29].
The age of the population is also a pivotal factor as the
Fig. 1 Milestones in Allergen ImmunoTherapy’s history. AIT, Allergen ImmunoTherapy; EPIT, Epicutaneous ImmunoTherapy; FDA, Food and drug
administration; IgE, immunoglobulin E; ILIT, Intralymphatic ImmunoTherapy; RDBPCT, Randomized, Double-Blind, Placebo-Controlled Trial; SCIT,
Subcutaneous ImmunoTherapy; SLIT, Sublingual ImmunoTherapy; Th, T cells helper; VIT, Venom Allergen ImmunoTherapy; WAO, World Allergy
Organization; WHO, World Health Organization
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phenotypic expression may change with age and some
manifestations may even disappear spontaneously [27–29].
The results of individual studies are difficult to compare
because studies have used not only different populations,
but also different methods (e.g. diagnostic criteria;
allergens, formulation, and strength of products used;
schedules; dose; route of administration; duration of the
intervention) and outcomes. Additionally, many studies
have small sample size and missing adjustment for con-
founders. Furthermore, not all AIT products used provide
sufficient data to support their efficacy in clinical practice.
Therefore, an individual product-based evaluation of the
evidence for efficacy is strongly recommended before treat-
ment with a specific product is initiated [5–7]. The identifi-
cation of the gaps in the current evidence is a preliminary
and mandatory phase in order to stimulate in the near
future the development of longitudinal, prospective, well-
designed studies with the final goal of a “precision
medicine/prevention”, tailored on each individual.
Prevention
Prevention is one of the major concerns, above all in
pediatrics. Furthermore, it is known that the clinical ex-
pression of respiratory allergies tends to change over
time, according to a “natural history”, the so-called
“atopic march”. In the typical sequence, allergic rhinitis
often precedes the onset of asthma and, therefore, it can
be considered a risk factor for the development of
allergic asthma [27–29]. In addition, there is often the
tendency to develop new sensitivities along time: the
natural history of sensitizations begins usually with
foods, continues with environmental allergens (usually
dust mites) and ends with pollens. However, some indi-
viduals begin their march only with sensitization to
mites, pollens or molds without food allergens [30]. Fur-
thermore, molecular-based diagnostics showed that in
most children the IgE response to a single allergenic
source evolves over time, becoming more and more
complex: the serum concentration of IgE antibodies rises
progressively, both for an increase sensitizing molecules,
and for a rising concentration of IgE antibodies directed
against any individual allergenic molecule (the so-called
phenomenon of “molecular spreading”) [30]. Interest-
ingly, a ‘pre-clinical’ IgE sensitization has been shown
already years before (up to 5 years before) the develop-
ment of seasonal allergic rhinitis, initially characterized
by weak and simple IgE responses, progressively increas-
ing in concentration and molecular complexity [30, 31].
Therefore, as AIT is the only disease-modifying treat-
ment in allergic diseases the potential preventing effects
of AIT have been suggested and investigated for the pre-
vention not only of the development of allergic comor-
bidities in patients with established allergic diseases, but
also the development of first allergic disease in not-sen-
sitized children (“primary immune-prophylaxis”) and in
still healthy children with specific IgE antibodies (“sec-
ondary immune-prophylaxis”) and allergic sensitization
in patients with other allergic conditions (“tertiary
Fig. 2 Proposed immunological mechanisms of action of immunotherapy: induction of Treg; production of IL-10 and TGF-β, cytokines to
upregulate regulatory dendritic cell (regDC) and immunomodulate target cells, such as B cells, mast cells/basophils with with downregulation of
IgE production by the production of IgG4, which are ‘blocking antibodies’
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immune-prophylaxis of atopy”) [4]. Certainly, alongside
efficacy, another pivotal issue to be considered is the
safety profile, especially in the context of prevention in
healthy individuals.
The current evidence suggests that a three-year-long
course of subcutaneous or sublingual AIT can be recom-
mended for children and adolescents with moderate to
severe AR due to grass or birch pollen in order to pre-
vent the onset of allergic asthma for up to 2 years
post-AIT cessation in addition to its sustained effect on
AR symptoms and medication [4, 32–37]. However, the
strength of this recommendation is moderate as based
on significant results from two moderate [33, 35] and
two high risk of bias [32, 34] RCTs and some controlled
before and after (CBA) studies. A few trials suggest a
preventive effect on the onset of asthma symptoms and
medication use longer than 2 years post-AIT [34, 35].
However, there is lack of evidence for AR triggered by
house dust mites or other allergens different from grass/
birch [4, 34, 38]. Overall, because of inconsistent results,
AIT cannot currently be recommended for the prevention
of new sensitizations, nor in patients with allergic rhinitis
and/or asthma nor in healthy individuals [4, 34, 39–41].
For lack of evidence, no recommendation can be made in
favor or against AIT in individuals with early life atopic
manifestation, such as atopic eczema and food allergy nor
in healthy subjects -with or without atopic sensitization-
for the prevention of onset of allergic diseases [4, 42].
Therefore, though there is evidence for the preventive po-
tential of AIT as disease modifying treatment, further
well-designed clinical trials are needed to confirm the pos-
sible value of AIT in prevention of allergic diseases. They
should consider the safety profile, the health-economic as-
pects, and the quality of life, too (Table 1). Additionally,
strategies need to be targeted to different scenarios, e.g.
women planning pregnancy to take preventive measures
such as AIT to reduce the risk that their child will de-
velop allergies, healthy infants and young children with
atopic dermatitis and food allergy, older children with
AR, healthy (with or without atopic sensitization) ado-
lescents/adults and adolescents/adults with established
allergic disease.
Allergic rhinitis
AIT is a therapeutic option in patients suffering from al-
lergic rhinitis/rhino-conjunctivitis with/without allergic
asthma with an evidence of specific IgE-sensitization to-
wards clinically relevant inhalant allergen(s) [2, 5, 43]. It
is indicated in the presence of moderate to severe symp-
toms interfering with usual daily activities or sleep (e.g.
Allergic Rhinitis and its Impact on Asthma, ARIA) [44]
despite avoidance measures and pharmacotherapy [2, 5].
Since AIT is allergen-specific, its efficacy and effective-
ness depends on a proper identification of the triggering
allergen(s). This concept fits into the perspective of a
“precision medicine” and implies a proper recording of
the clinical history and ascertainment of environmental
exposure [45], confirmed by diagnostic tests [46]. Before
prescribing AIT, any specific patient-related (e.g. uncon-
trolled or severe asthma and adherence to the treatment)
and product-specific absolute or relative contraindica-
tions should be considered.
Sublingual (SLIT) and subcutaneous (SCIT) allergen
immunotherapy constitutes the preferred route of ad-
ministration of AIT for respiratory allergies. Alternative
modalities of delivery [such as epicutaneous [47], intra-
dermal [48] and intralymphatic routes [49]] have been
recently under investigation, however with currently
modest body of evidence [2]. In general, the current evi-
dence suggests that both SCIT and SLIT are effective for
AR [2, 5]. Both route of administration were associated
with reductions in symptoms and with medication use.
The strength of evidence is high in adult patients but
moderate in pediatric patients for lack of data [2, 5]. In
particular, in children suffering from moderate to severe
seasonal AR, both continuous and pre- (i.e. AIT started
at least 2, preferable 4 months before the pollen season)
and pre−/co-seasonal AIT are currently recommended for
clinical benefit during the AIT treatment [2, 5, 50–57].
Overall, there are insufficient data to determine which of
SCIT and SLIT is the most effective [2, 5]. Concerning
perennial AR due to house dust mites, there is evidence
for efficacy of continuous AIT (both SCIT and SLIT, the
latter in form of tablet but not in aqueous solution) during
the AIT treatment [2, 5, 58, 59]. The evidence for clinical
benefit to pediatric patient for at least 1 year after cessa-
tion of the AIT course (the so-called “long-term efficacy”)
nowadays is limited to continuous grass pollen AIT (both
SLIT -tablet or solution- and SCIT) performed for a
minimum of 3 years in seasonal AR due to grass
Table 1 Gaps in the evidence of AIT for prevention
Major gaps in the evidence of prevention
❖ Long-term effectiveness of AIT in preventing asthma in children with
AR due to grass pollen
❖ Effectiveness of AIT in preventing asthma in children with AR due to
house dust mites
❖ Identification of the optimal age for introduction of AIT for
prevention
❖ Identification of the optimal duration of AIT for prevention
❖ Identification of the optimal product, administration form, dose and
schedule of AIT for prevention
❖ Evaluation of healthy economics of AIT for prevention
❖ Evaluation of acceptability of AIT for prevention in different patient
groups (age, pattern of sensitization and clinical characteristics) and
healthy individuals
❖ Identification of the most suitable candidates
❖ “Precision preventive medicine” algorithms
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pollen [2, 5, 50, 60]. No study to our knowledge have in-
vestigated the long-term efficacy of AIT in perennial AR
in children however there is evidence for continuous ther-
apy with SLIT tablet in adults with AR to house dust mite
[61]. In addition, evidence to support SLIT in children
with asthma due to HDM is still scarce [62]. Many factors
may affect the efficacy of AIT. Some factors are related to
the patient, including poly-sensitization, co-existing
asthma and specific issues in pre-school age. Other factors
are related to the allergen(s), such as: the standardization
of allergen extracts (including common allergens- whose
characterization is still missing in many commercial
products and/or lacking stability, e.g. molds- and “orphan
allergen”, affecting a few patients); the formulation of
SLIT preparation and allergen mixtures (some allergens
with enzymatic activity, such as HDM, may affect the effi-
cacy of SLIT drops). A careful evaluation of the indica-
tions to AIT and individual product-based evaluation of
the evidence for efficacy is pivotal before prescribing a
specific AIT product. Standardized AIT products with
documented clinical evidence of efficacy should be used
when available [2, 5]. Unfortunately, among the published
data there is a substantial heterogeneity in terms of the
study design (particularly the different outcomes used),
study population and the products evaluated. This hetero-
geneity -as discussed above- hampers the meta-analyses
and comparison among the available data [2, 5].
Many gaps are still unmet (Table 2): more prospective
multi-centre controlled trials using standardized products
are awaited in order to address them. New combined
approaches have been suggested and experimented in
order to improve adherence and quality of life with
shorter courses, whilst reducing the risk of adverse reac-
tions and improving the effectiveness [63]. For instance,
adjuvants have been added to AIT extracts [e.g. TLR-4
agonists [64–67], TLR-9 agonists [68]] with promising
results in adults. Anti-IgE injections have been combined
with AIT schedules with safer profile and maintained
effectiveness also in children. However, this approach is
expensive and there is no agreement on timing and mode
of anti-IgE discontinuation when AIT maintenance is
achieved [69, 70]. Another attractive approaches lies on
the use of recombinant AIT as it allows accurate
standardization of allergen products, and potentially a per-
sonalized treatment based on the individual allergic
sensitization(s) [71]. Further studies are awaited to further
investigate these interesting approaches.
Food allergy
IgE-mediated food allergy (FA) is a potentially life-
threatening condition [72], with a negative impact on
the quality of life of patients and their family [73, 74].
The current standard approach consists of the strict
avoidance of the culprit food and rescue medication in
the event of an allergic reaction occurs [75]. However,
an elimination diet may be difficult and frustrating in
patients with persistent FA, above all for those foods
(e.g. cow’s milk, CM, and hen’s egg, HE) that are central
in the common diet [75]. Nevertheless, despite efforts to
comply with this diet, accidental exposures leading to
adverse reactions are frequent [76, 77]. In this context,
considering the potential desensitizing effects of allergen
administration, AIT has been investigated. The most fre-
quent route of administration consists of the immediate
swallowing of the allergen (oral immunotherapy, OIT).
On the basis of the current body of evidence, OIT is per-
formed more and more in clinical practice, though still
in a few rate of eligible patients. OIT involves the ad-
ministration of increasing doses of the culprit allergen
until the food is tolerated at usually dietary doses. This
approach can confer protection against accidental aller-
gic reactions and contribute to improve nutritional sta-
tus and quality of life of the affected patients [74]. Many
clinical trials performed with cow’s milk, hen’s egg and
peanuts consistently show that an effective increase of
the threshold of reaction while on OIT (desensitization)
can be obtained, and therefore recommended, in chil-
dren with persistent FAs, from around 4–5 years of age
as most patients overcome their FAs to CM and HE
spontaneously. However, it is not clearly defined if when
desensitization has been achieved, a permanent toler-
ance persists, independent of the regular assumption of
the responsible food [3, 6, 78, 79]. Adverse events may
occur but most of them are not severe [6]. It can be
Table 2 Gaps in the evidence of AIT for allergic rhinitis
Major gaps in the evidence of AIT for allergic rhinitis
❖ Lack of agreement on clinically relevant outcomes of effectiveness
and clinically meaningful effect size of AIT (active vs placebo)
❖ Lack of evidence of clinical effectiveness for some products
❖ Lack of standardized AIT preparations for “orphan allergens”
❖ Lack of evidence for effectiveness of mixtures of homologous
allergens
❖ Evidence for long-term clinical effectiveness after discontinuation
treatment
❖ Standardization of grading of adverse effects of AIT
❖ Approaches to minimize adverse effects
❖ Good evidence base for contraindicating AIT
❖ Approaches to improve adherence to AIT
❖ Role of adjunctive treatment(s) (e.g. omalizumab)
❖ Cost-effectiveness and cost-utility studies
❖ Good understanding of mechanisms of action
❖ Identification of biomarkers of response, to predict and quantify the
effectiveness of AIT
❖ Identification of the most suitable candidates
❖ “Precision medicine” algorithms
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performed only in highly specialized centers and under
strict medical supervision after the informed consent has
been obtained from parents [3, 6, 80–82]. Other routes
of administration have been investigated (e.g. sublingual,
subcutaneous and epicutaneous ones) [83–86] as well
as adjunctive treatments (such as omalizumab and
probiotics) [87–89]. Though AIT represents an emerging
reality as an active treatment for IgE-mediated food aller-
gies, many issues remain unanswered. Clinical trials for
OIT so far conducted are extremely heterogeneous and
therefore their results are not comparable. Differences
encompass dosage, amount and frequency, duration of
build-up and maintenance phases, type of allergen used,
patient characteristics, reporting in adverse events and ad-
juvant therapies (Table 3) [78]. Much larger, longitudinal
and well-designed studies using more homogenous proto-
cols are needed in order to standardize products and to
validate protocols (optimal doses and schedule), to assess
the sustainability of the desensitization process, to
improve the effectiveness after AIT discontinuation, the
safety, and the impact on quality of life, and to identify the
role of adjunctive therapies (such as omalizumab and
probiotics) [78].
Conclusions
Through an overview of the up-to-date evidence in
terms of mechanisms of action, efficacy and safety of
AIT for prevention, allergic rhinitis and food allergy, this
rostrum sought to gauge the main needs currently un-
met in AIT in order to stimulate in the near future the
development of longitudinal, prospective, well-designed
studies with the final goal of a “precision medicine”
tailored on each single eligible subject [90, 91]. A deep
understanding of mechanisms of action will improve the
current strategies and provide new ones for immune
intervention, which will likely include targeting of the
molecular mechanisms of allergen tolerance and recipro-
cal regulation of effector and regulatory T cell subsets.
The molecular-based diagnostics would certainly im-
prove the accuracy in AIT prescription, allowing to dis-
sect the genuine sensitizations and the cross-reactions
due to pan-allergens [92]. Mobile health technologies
might establish a cause-effect relationship between ex-
posure to the pollen recognized by the patient’s IgE
sensitization pattern and the patient’s symptoms and
precisely assess the degree of severity of the patient’s
symptoms, as AIT should be administered primarily to
patients with moderate-severe rhinitis [2]. An integrated
approach combining different available diagnostic tools
might achieve a more precise etiological diagnosis for a
better AIT prescription. However, to our best know-
ledge, no informatics tool dedicated to support the im-
plementation of internationally validated algorithm is so
far available. Furthermore, the development of integrated
care pathways incorporating (educating and training)
primary and secondary care, as well as the availability of
high quality AIT products, individual product-based
evaluation of the evidence, and global actions aimed to
develop a harmonized international approach to regulate
AIT products are awaited in order to implement AIT in
clinical practice. The interest and the attention to AIT
treatment are currently fervent and increasing. Well-de-
signed studies are awaited in the near future in order to
overcome the current gaps in the evidence and furtherly
promote implementation strategies.
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❖ Good understanding of mechanisms of action
❖ Identification of biomarkers of response
❖ Identification of the most suitable candidates
❖ “Precision medicine” algorithms
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